

Research

Retinopathy of prematurity in Kenya: prevalence and risk factors in a hospital with advanced neonatal care



Oscar Onyango¹, Sarah Sitati^{2,8}, Lucia Amolo³, Florence Murila³, Susan Wariua³, Gacheri Nyamu³, Moses Lango³, Atul Patel³

¹Nairobi Hospital, Department of Ophthalmology, Nairobi, Kenya, ²Sabatia Eye Hospital, Department of Pediatric Ophthalmology, Wodanga, Kenya, ³Nairobi Hospital, Department of Neonatology, Nairobi, Kenya

⁸Corresponding author: Sarah Sitati, Sabatia Eye Hospital, Department of Pediatric Ophthalmology, Wodanga, Kenya

Key words: Retina, retinopathy, child eye health, prematurity, neonatal health, premature, retinopathy of prematurity

Received: 05/10/2017 - Accepted: 05/03/2018 - Published: 15/03/2018

Abstract

Introduction: Increased survival of preterm babies in sub-saharan Africa has held to an increasing prevalence of Retinopathy of prematurity (ROP). This study was done to determine the ROP prevalence in a hospital with advanced neonatal care in urban Kenya. **Methods:** A hospital-based retrospective review of the records of premature infants screened for ROP between January 2010 and December 2015. Records of all premature infants screened for ROP in the neonatal unit and outpatient eye clinic were extracted. Information on Birth weights, Gestational age, Maternal risk factors (mode of delivery, pre-eclampsia/eclampsia) and Neonatal risk factors (neonatal sepsis, days on oxygen, blood transfusion) was recorded in a questionnaire then analysed. **Results:** 103 infants were included in the study. Mean gestational age was 29.9 ± 2.2 weeks and the mean birth weight was 1280.1 ± 333.0 grams. Forty-three infants were diagnosed with ROP, a prevalence of 41.7%. Majority of these had Stage 1 or 2 ROP in Zone II, which spontaneously regressed with follow up. Nine infants were diagnosed with vision-threatening ROP (any Zone I disease or Stage 2/3 disease in Zone II with plus disease), a prevalence of 20.9%. All of these underwent laser treatment in the neonatal unit. The most significant risk factor was low gestational age. Other risk factors identified were: low birth weight and blood transfusions. **Conclusion:** ROP prevalence in sub-saharan Africa will match those in middle-income and high income countries in neonatal units with advanced care and low mortality.

Pan African Medical Journal. 2018;29:152. doi:10.11604/pamj.2018.29.152.14046

This article is available online at: <http://www.panafrican-med-journal.com/content/article/29/152/full/>

© Oscar Onyango et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

About 60% of the world's preterm births occur in sub-Saharan Africa and Asia. In Kenya, pre-term births are estimated at 12.3% [1]. With improved neonatal systems in developing countries, survival rates for premature infants have increased [2, 3]. Many of these infants survive with disabilities, including visual complications. Retinopathy of prematurity (ROP) is now emerging as an important cause of ocular morbidity in low and middle income countries [4, 5]. Despite this, little is known about ROP in sub-Saharan Africa, Kenya included [2]. Lack of information has hampered the development of screening programs that would aid early detection and treatment of ROP. ROP screening and treatment has been ongoing in Nairobi Hospital since 2010. Survival rates for preterm infants is high and ROP has been identified as an upcoming epidemic in this hospital. This study was done to determine the prevalence and risk factors associated with ROP in a hospital with advanced neonatal care in a developing country.

Methods

A hospital-based retrospective review of the records of premature infants screened for ROP between January 2010 and May 2015. The Nairobi Hospital is a modern private hospital with advanced neonatal care, located in Kenya's capital of Nairobi. Neonatal care in this institution is comparable to that in many middle and high income countries. The hospital has a well-equipped neonatal unit, including a neonatal intensive care unit (NICU). There are five neonatologists, several resident pediatricians and trained neonatal unit nurses working in the unit. Ethical approval was obtained from the Nairobi Hospital Ethical Review Committee. A consent waiver was requested and approved prior to examination of patient records. Records of all premature infants born within the study period and screened for ROP in the neonatal unit and outpatient eye clinic were extracted. Information on Birth weights, Gestational age, Maternal risk factors (mode of delivery, pre-eclampsia/eclampsia) and Neonatal risk factors (neonatal sepsis, days on oxygen, mechanical ventilation, blood transfusion) was recorded in a questionnaire then analysed. The hospital has an in-house screening program and all babies born < 32 weeks gestational age or weighing ≤ 1500 grams are referred to the ophthalmologist for review. High risk infants who fall outside the screening criteria are also referred, for example, those with prolonged hospital stays due

to mechanical ventilation, neonatal sepsis and surgical cases. A tracking system in the unit ensures that appointment reminders are given by the neonatologist/ pediatrician during clinic visits. Infants included in the study had been examined by a single vitreo-retinal specialist starting at 28 days of life and followed up one-two weekly until achievement of full retinal vascularisation or achieving 50 weeks post-natal age. Those with Type 1 ROP (any Zone I disease, Stage 2-3 disease in zone II with plus disease) received laser treatment within the neonatal unit within 48 hours of diagnosis. Those with Type 2 ROP (Stage 1-2 without plus in zone I, Stage 2-3 without plus in zone II) were followed up two weekly until regression of ROP or until vascularisation in zone III was achieved. On achieving zone III vascularisation, infants were then referred to the pediatric ophthalmologist for follow up.

Results

71,888 infants were admitted to the Nairobi hospital neonatal unit during the study period. Of these, 148 were classified as premature (gestational age <37 weeks). 103 had been screened for ROP in the neonatal unit and outpatient eye clinic and the records of these infants were all retrieved. The male to female ratio was 1:1.1, with 54 (52%) males and 49 (47%) females. Mean gestational age was 29.9 ± 2.2 weeks and the mean birth weight was 1280.1 ± 333.0 grams. Table 1 shows a summary of the socio-demographic characteristics of included infants. Forty-three infants were diagnosed with ROP, a prevalence of 41.7%. Table 2 gives a summary of the ROP descriptions among the premature infants and their progression through subsequent follow up visits. Majority of these had Stage 1 or 2 ROP in Zone II, which regressed with follow up. The mean birth weight in this group was 1207.4 grams and mean gestational age 29.1 weeks. 17/43 (39.5%) received blood transfusions while in the neonatal unit, and 10/43 (23.3%) were diagnosed with neonatal sepsis. 33/43 (76.7%) were on mechanical ventilation. The main maternal risk factor identified was eclampsia/pre-eclampsia, with 12/43 (27.9%) infants having this risk. Nine infants were diagnosed with vision-threatening ROP (any Zone I disease or Stage 2/3 disease in Zone II with plus disease), a prevalence of 20.9%. All of these underwent laser treatment in the neonatal unit. Table 3 shows the socio-demographic data and risks identified in those with vision-threatening ROP. Finally, Table 4 shows the risk factors associated with development of ROP in this group of premature infants and their significance ($p < 0.05$). The

strongest risk factor for development of ROP was gestational age, followed by mechanical ventilation. Other significant risk factors included low birth weight and presence of blood transfusion. Although neonatal sepsis was present in more than half of the infants who developed ROP requiring treatment (5/9; 55.6%), it did not have statistical significance when the larger group was examined.

Discussion

The question of whether or not ROP is an upcoming epidemic in Africa has been under debate for some years now. Data on ROP in sub-Saharan Africa is scanty and studies in the schools for the visually impaired and hospitals in eastern Africa show low prevalence of retinal diseases, ROP included [6-8]. It is thought that high neonatal mortality in low income countries, especially among prematures, has contributed to this trend [2]. Neonatal systems in Africa have improved in the recent past, renewing the question of ROP prevalence. The above study shows that ROP prevalence will match those in middle and high income countries in hospitals with advanced neonatal care. The prevalence of ROP in this study was 41.7%. Adio et al in Nigeria demonstrated a similar picture, with an ROP prevalence of 47.2% [9]. This prevalence matches those in middle-income countries where ROP has been identified as a new epidemic [10, 11]. It is however higher than that noted in a previous Kenyan study done in the same city. Wanjala et al, in a study done in two government hospitals in Kenya, had an ROP prevalence of 16.8% [12]. It is not uncommon to find varying ROP prevalences within the same country, depending on the level of neonatal care present [2]. Variation in infant mortality could also account for these differences. The infant mortality recorded during this study was 4.6% versus that recorded by Wanjala et al at 24.5%. Studies have also shown that infant mortality is skewed towards lower gestational age and birth weight [13], thus the cohort with the highest likelihood of developing ROP is also the one that is least likely to survive. This is especially true of sub-saharan African countries, where neonatal services are poorly developed. Low gestational age and low birth weight have been consistently identified as important risk factors for development of ROP [14-18]. Our study therefore shows that ROP prevalence is directly proportional to neonatal mortality and that improved neonatal systems may change picture of ROP blindness with time within the same setting [19, 20]. In the ROP descriptions, majority of the

infants were found to have Type 2 ROP (non-vision threatening), most of which regressed spontaneously with follow up. Nine infants (9/103 (9.3%)) were diagnosed with Type 1 (vision threatening) ROP and underwent laser treatment in the neonatal unit by a retina specialist. Prevalences of vision-threatening ROP vary in different countries and with different races. Black race has also been thought to be a protective factor in development of vision-threatening ROP [21, 22]. This theory was supported by a Nigerian study where, despite a high ROP prevalence of 47.2%, none of the infants developed ROP requiring treatment [9]. The picture shown in our study was different, with vision threatening ROP matching that seen in middle income and high income countries with good neonatal care [23-25]. We propose the theory that black infants are just as likely to develop vision threatening ROP as those of other races. However, all the children in this study were of black African race, thus it was not possible to make a significant race comparison. When examining the risk factors associated with vision-threatening ROP, univariate analysis showed that gestational age was the most predominant risk factor followed by mechanical ventilation, low birth weight and blood transfusions. Several risk factors have been consistently identified for development of ROP, and those in this study matched with other studies [15, 23, 26, 27]. Although sepsis was not a significant risk factor in our study, other African studies have identified it as an important factor in the development of ROP [9,12]. This study had a limitation of being a retrospective study. Despite having no missing records, a prospective study would have been more useful in determining the ROP prevalence.

Conclusion

In conclusion, the Nairobi hospital study shows that ROP prevalence in Africa will match that in other countries as neonatal care continues to improve. While hospitals with poor neonatal care may continue to see scanty ROP cases, hospitals with advanced neonatal care must develop rigorous screening programs so that no case of ROP is missed.

What is known about this topic

- Preterm births are high in sub-Saharan Africa;
- Data on ROP prevalence in developing countries is scanty;
- Black race is protective to development of vision-threatening ROP.

What this study adds

- This study contributes to data on ROP prevalence rates in Kenya and sub-Saharan Africa;
- It shows that ROP prevalence in low income countries can match that in middle and high income countries when neonatal services are well developed;
- It shows that the prevalence of vision-threatening ROP in black infants is comparable to that of infants of other races.

Competing interests

The authors declare no competing interests.

Authors' contributions

Oscar Onyango: proposal development, ERC approval, data collection, data analysis, manuscript drafting, approval of final manuscript for submission. Sarah Sitati: Proposal development, data analysis, Manuscript drafting, critical revision of article, approval of final manuscript for submission. Lucia Amolo: proposal development, ERC approval, Data collection, data analysis. Atul Patel: proposal development, ERC approval, data collection, data analysis. Florence Murila: proposal development, data analysis, Critical revision of article, approval of final manuscript for submission. Susan Waruia: proposal development, data analysis, critical revision of article, approval of final manuscript for submission. Gacheri Nyamu: proposal development, data analysis, critical revision of article, approval of final manuscript for submission. Moses Lango: proposal development, data analysis, critical revision of article, Approval of final manuscript for submission. All the authors have read and agreed to the final manuscript.

Tables

Table 1: Socio-demographic characteristics of premature infants, n = 103

Table 2: ROP Descriptions, n = 86 eyes

Table 3: Descriptions of infants with ROP requiring treatment, n = 9

Table 4: Risk factors among infants with ROP (n = 103)

References

1. Blencowe H et al. Born too soon: the global epidemiology of 15 million preterm births. *Reprod Health*. 2013; 10 Suppl 1: S2. **PubMed | Google Scholar**
2. Gilbert C et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate and high levels of development: implications for screening programs. *Pediatrics*. 2005; 115(5): e518-25. **PubMed | Google Scholar**
3. Dogra MR, Katoch D. Retinopathy of Prematurity: an emerging and evolving challenge. *Indian J Ophthalmol*. 2017; 65(9): 782-784. **PubMed | Google Scholar**
4. Gilbert C et al. Retinopathy of prematurity in middle-income countries. *Lancet*. 1997; 350(9070): 12-4. **PubMed | Google Scholar**
5. Dave HB et al. The societal burden of blindness secondary to retinopathy of prematurity in Lima, Peru. *Am J Ophthalmol*. 2012; 154(4): 750-5. **PubMed | Google Scholar**
6. Njuguna M et al. Causes of severe visual impairment and blindness in children in schools for the blind in eastern Africa: changes in the last 14 years. *Ophthalmic Epidemiol*. 2009; 16(3): 151-5. **PubMed | Google Scholar**
7. Ruhagaze P et al. Blindness and severe visual impairment in pupils at schools for the blind in Burundi. *Middle East Afr J Ophthalmol*. 2013; 20(1): 61-5. **PubMed | Google Scholar**
8. Demissie BS, Demissie E. Patterns of eye diseases in children visiting a tertiary teaching hospital: South-western Ethiopia. *Ethiop J Health Sci*. 2014; 24(1): 69-74. **PubMed | Google Scholar**
9. Adio AO et al. Retinopathy of prematurity in port harcourt, Nigeria. *ISRN Ophthalmol*. 2014; 2014: 481527. **PubMed | Google Scholar**

10. Quinn GE et al. Retinopathy of prematurity: an epidemic in the making. *Chin Med J (Engl)*. 2010; 123(20): 2929-37. **PubMed | Google Scholar**
11. Quinn GE. Retinopathy of prematurity in Brazil: an emerging problem. *J Pediatr (Rio J)*. 2007; 83(3): 191-3. **PubMed | Google Scholar**
12. Wanjala I, Ilako D, Kariuki L. Retinopathy of Prematurity as seen in two major hospitals in Nairobi, Kenya. *East Africa Journal of Ophthalmology*. May 2007; 13(1): 5-14. **Google Scholar**
13. Reynolds JD et al. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. *Arch Ophthalmol*. 2002; 120(11): 1470-6. **PubMed | Google Scholar**
14. Gerull R et al. Incidence of retinopathy of prematurity (ROP) and ROP treatment in Switzerland 2006-2015: a population-based analysis. *Arch Dis Child Fetal Neonatal Ed*. 2017. **Google Scholar**
15. Ali NA et al. Prevalence of retinopathy of prematurity in Brunei Darussalam. *Int J Ophthalmol*. 2013; 6(3): 381-4. **PubMed | Google Scholar**
16. Xu Y et al. Screening for retinopathy of prematurity in China: a neonatal units-based prospective study. *Invest Ophthalmol Vis Sci*. 2013; 54(13): 8229-36. **PubMed | Google Scholar**
17. Afarid M, Hosseini H, Abtahi B. Screening for retinopathy of prematurity in South of Iran. *Middle East Afr J Ophthalmol*. 2012; 19(3): 277-81. **PubMed | Google Scholar**
18. Demir S et al. Retinopathy of prematurity in extremely low birth weight infants in Turkey. *J Pediatr Ophthalmol Strabismus*. 2013; 50(4): 229-33. **PubMed | Google Scholar**
19. Vinekar A et al. Impact of improved neonatal care on the profile of retinopathy of prematurity in rural neonatal centers in India over a 4-year period. *Eye Brain*. 2016; 8: 45-53. **PubMed | Google Scholar**
20. Sommer A et al. Challenges of ophthalmic care in the developing world. *JAMA Ophthalmol*. 2014; 132(5): 640-4. **PubMed | Google Scholar**
21. Saunders RA et al. Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. *Arch Ophthalmol*. 1997; 115(5): 604-8. **PubMed | Google Scholar**
22. Port AD et al. Risk factors for retinopathy of prematurity: insights from outlier infants. *Graefes Arch Clin Exp Ophthalmol*. 2014. **Google Scholar**
23. Ludwig CA et al. The Epidemiology of Retinopathy of Prematurity in the United States. *Ophthalmic Surg Lasers Imaging Retina*. 2017; 48(7): 553-562. **PubMed | Google Scholar**
24. Ugurbas SC et al. Comparison of UK and US screening criteria for detection of retinopathy of prematurity in a developing nation. *J AAPOS*. 2010; 14(6): 506-10. **PubMed | Google Scholar**
25. Zin AA et al. Retinopathy of prematurity in 7 neonatal units in Rio de Janeiro: screening criteria and workload implications. *Pediatrics*. 2010; 126(2): e410-7. **PubMed | Google Scholar**
26. Holmström GE et al. Swedish national register for retinopathy of prematurity (SWEDROP) and the evaluation of screening in Sweden. *Arch Ophthalmol*. 2012; 130(11): 1418-24. **PubMed | Google Scholar**
27. Lad EM et al. Retinopathy of prematurity in the United States. *Br J Ophthalmol*. 2008; 92(3): 320-5. **PubMed | Google Scholar**

Table 1: Socio-demographic characteristics of premature infants, n=103

Variable	Frequency (%)
Male	54 (52.4)
Female	49 (47.6)
Mean Gestational Age at birth (Weeks)	29.9 ± 2.2
Range	25-37
Mean Birth Weight (Grams)	1280.1 ± 333.0
Range	650-1890
Mean Maternal age (Years)	33.3 ± 5.8
Range	23-50
Mode of delivery	
C/S	79 (76.7)
SVD	24 (23.3)
Mean post-natal age (PNA) at first exam (Days)	34.3 (2.2)
Range	30-42

Table 2: ROP Descriptions, n=86 eyes

Variable	RE			LE		
	Initial exam (n=43)	Follow up 1 (n=14)	Follow up 2 (n=3)	Initial exam (n=41)	Follow up 1 (n=8)	Follow up 2 (n=1)
Stage						
1	30	7	1	23	2	0
2	12	6	1	13	6	1
3	1	1	1	2	0	0
Zone						
1	2	0	0	0	0	0
2	16	9	0	15	1	0
3	20	3	2	17	6	1
Plus disease						
Mild	10	4	1	8	3	0
Moderate	3	1	0	1	0	0
Marked Plus disease	2	1	1	3	1	0
No plus disease	28	0	0	31	10	0

Table 3: Descriptions of infants with ROP requiring treatment, n = 9

Variable	Frequency (%)
Mean Birth Weight (grams)	29.2 ±1.8
Range	26.0-32.0
Mean Gestational Age (weeks)	1184 ±271.0
Range	870-1660
Days on mechanical ventilation	7 ±77.8
Median (IQR)	3 (1-10)
Baby with neonatal sepsis	
Yes	5 (55.6)
No	4 (44.4)
Received blood transfusion	
Yes	5 (55.6)
No	4 (44.4)
Mother diagnosed with eclampsia/pre-eclampsia	
Yes	3 (33.3)
No	6 (66.7)

Table 4: Risk factors among infants with ROP (n=103)

	ROP diagnosed		P value (p<0.05)
	Yes (%)	No (%)	
Mean gestation age at birth (SD)	29.1 (1.9)	30.6 (2.2)	< 0.001
Range	25.0 - 33.0	26.0 - 37.0	
Mean birth weight (SD)	1207.4 (254.9)	1334.4 (301.5)	0.027
Range	725.0 - 1800.0	650.0 - 1890.0	
Documented sepsis			
Yes	10 (25.0)	10 (17.9)	0.396
No	30 (75.0)	46 (82.1)	
Baby got blood transfusion			
Yes	17 (40.5)	11 (19.0)	0.018
No	25 (59.5)	47 (81.0)	
Blood-culture positive sepsis			
Yes	3 (8.1)	1 (1.9)	0.302
No	34 (91.9)	52 (98.1)	
Baby required mechanical ventilation			
Yes	33 (78.6)	29 (50.0)	0.004
No	9 (21.4)	29 (50.0)	